Therapeutic areas
Arthritis and immunology
Cardiometabolic health
Dermatology
Neurology and mental health
Oncology
Policy and methods
Rare diseases
Respiratory
Arthritis and immunology
In this rapidly evolving area, gaps in available evidence must be addressed in a proactive way that captures treatment nuances. We apply patient-level simulation, health-related quality of life mapping, and other advanced methods of technical analysis to provide customised solutions for gaining market access for your drug.
We have assisted clients in winning market access for several blockbuster medicines in idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis and other auto-immune conditions. During this work, we have spearheaded highly cited research publications and successful submissions to health technology assessment (HTA) bodies.
Success story: supporting the global market access strategy for an immunology drug.
Publications:
Cardiometabolic health
Cardiometabolic diseases are the most common cause of death around the world. While advances in medicine have improved the treatment and management of these conditions, their global prevalence continues to grow.
We can help you bring game-changing treatments to patients faster. We have produced numerous global cost-effectiveness models for medicines and devices in this area for clients in the UK, US and farther afield. Our work has led to several highly cited research publications and successful submissions to HTA bodies.
Success story: evaluating the cost-effectiveness of a diagnostic device.
Publications:
Dermatology
Dermatological conditions may not be life-threatening, but they can have a debilitating impact on patients’ quality of life.
We can help you perform industry-leading research in this area, develop convincing pricing strategies as well as navigate complex, constantly evolving HTA processes – giving your drug or device the best chances of market access. Working in dermatological conditions such as psoriasis and atopic dermatitis, we have spearheaded several highly cited publications, developed numerous global models and adapted them to specific countries. We have conducted network meta-analyses appraised by industry peers at the Professional Society for Health Economics and Outcomes Research (ISPOR) as an innovative way to overcome missing data.
Publications:
Neurology & mental health
When dealing with an organ as complex as the brain, you need a partner with unrivalled experience in evidence reviews and economic modelling in order to rise above the complexity and chart a course for your drug or device.
We can help you navigate the complexities of mental health and neurological conditions and the intricacies of available evidence within this area in order to streamline your decision-making and optimise your approach to the market. We have helped our international clients anchor their research and development for neurological conditions such as dementia and epilepsy. We also have deep experience demonstrating the value of interventions against mental health conditions including bipolar disorder, depression, and schizophrenia.
Success story: we supported a device manufacturer with early-stage value demonstration in epilepsy.
Publications:
Sawyer L, Azorin JM, Chang S, Rinciog C, Guiraud-Diawara A, Marre C, Hansen K. (2014) ‘Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. Journal of Medical Economics; 17(7):508-19.
Oncology
Cancer is the target of a substantial share of new medicines that enter the market, and this share continues to grow. Likewise, a large share of our work at Symmetron focuses on oncology. We have helped clients in Canada, Ireland, the UK, and to gain market access for their drugs against breast, colorectal, lung, thyroid, lymphoma, and other cancers.
Success story: overcoming limited evidence to gain reimbursement for a blockbuster oncology drug.
Publications:
Policy and methods
Experts at Symmetron have followed career paths in government, academia and industry, and our diversity makes us uniquely suited to analyse healthcare challenges from a 360-degree perspective. We believe that good consulting practice means identifying industry needs and seeking to address them.
We have carried out industry-leading research in numerous areas of healthcare that cut across several therapeutic areas, including medicines access, outcomes-based contracts, global HTA requirements, patient priority outcomes, and HTA for immune-oncology medicines. This is all part of our core mission of helping clients bring medicines and devices to market in order to increase healthcare access and improve patients’ quality of life.
Publications:
Rare diseases
Rare diseases lack the large market to attract certain kinds of investment, yet many are debilitating and reflect inequities in global healthcare.
We help clients who have the courage and flexibility to step into this less-chartered territory by helping them assess the underdeveloped evidence base. For this work, we sometimes draw on the award-winning methods and strategies that we have developed to understand and overcome evidence gaps related to major diseases. Occasionally, however, we need to apply or even innovate new methods that take into account the particularities of rare conditions. We have helped clients target a broad range of rare diseases, including anaemia, haematology, respiratory conditions, idiopathic pulmonary fibrosis, progressive medullary thyroid cancer, giant cell arthritis, and haemophilia B.
Success story: modelling long-term survival for rare disease patients after the trial period.
Publications:
Diamantopoulos A, Wright E, Vlahopoulou K, Cornic L, Schoof N, Maher TM. (2018) ‘The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review’. PharmacoEconomics; 36:779–807.
Respiratory
Here, we have developed a strong footprint in the industry through our innovative research as well as our support during regulatory submissions. We have published highly cited analyses of lung disease, and we have helped clients in Europe, South Korea and China achieve market access.
Success story: gaining reimbursement for a drug targeting a respiratory condition.
Publications: